News & Events

T 0883/23: Dosage claims and their entitlement to priority when only the clinical trial protocol was disclosed in the priority application

In a recently issued decision by the EPO’s Board of Appeal (BoA), the BoA held that claims directed to a combination of active pharmaceutical ingredients (APIs) at particular doses were …

Read article

The end of the Brexit overhang for trade marks: review, refile and revoke.

On the 31st December 2025, five years will have passed since the end of the Brexit transitional period on 31st December 2020. Why is this relevant? For UK cloned trade …

Read article

Mycelium Meets Market Reality: The Quiet Role of IP in Scaling Sustainable Materials

Fungal materials are increasingly used in applications ranging from sustainable packaging and leather alternatives to construction composites, textiles, and biotechnology. These developments are transforming fungi from a niche research subject …

Read article

From Stripes to Supermarkets: The Court of Appeal Reaffirms the Need for Precision in Trade Mark Law

On 23 October 2025, Lord Justice Arnold delivered two landmark Court of Appeal decisions addressing trade mark registrability: Thom Browne Inc & Anor v adidas AG [2025] EWCA Civ 1340 …

Read article

Protecting Digital Health innovation in the AI revolution

As artificial intelligence (AI) continues to transform healthcare, from diagnostic imaging and drug discovery to wearable devices and clinical decision support, questions around how to protect these advancements have become …

Read article

Protect It Before You Promote It: IP Advice for MedTech Innovators

Developed a new medical product? Check. Got tickets to an exciting MedTech conference to show off your new product? Check. Intellectual property? Pardon? In the excitement of bringing a new …

Read article

How France’s investment in digital health, AI, and bioinformatics is transforming the intellectual property (IP) landscape

In recent years, France has become a key player in digital health innovation, driven by strategic government investments under the France 2030 initiative and the French Tech 2030 program. These …

Read article

A Turning Point for AI Patent Eligibility?

Director Squires Vacates PTAB § 101 Rejection in DeepMind Case In a notable early move as Under Secretary of Commerce and USPTO Director, John Squires has vacated a Patent Trial …

Read article

T 0792/24: Novelty and Inventiveness of Second Medical Use Claims

The EPO Board of Appeal’s decision in T 0792/24 provides helpful guidance on the assessment of novelty and inventive step for European second medical use claims. In light of a …

Read article